Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 60

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 60
---
 respect to securities. Common Shares subject to options or warrants currently exercisable, or exercisable within 60 days of March 28, 2025, are counted as outstanding for computing the percentage of the individual or entity holding such options or warrants but are not counted as outstanding for computing the percentage of any other individual or entity. (2)Consists of (i) 5,621,494 NLS Common Shares, (ii) 211,466 NLS Common Shares issuable upon exercise of options vested and exercisable within 60 days of March 28, 2025, (iii) 189,012 NLS Common Shares held by Revel Family Ltd., and (iv) 189,012 NLS Common Shares issuable upon exercise of common warrants held by Revel Family Ltd. exercisable within 60 days of March 28, 2025, subject to a beneficial ownership limitation of 9.99%. Revel Family Ltd. is controlled by Michel Revel, its sole equity owner, who holds voting and dispositive power over the securities. The address of Revel Family Ltd. is 52 HaNasi HaRishon Street, Rehovot, Israel, 7630242. (3)Consists of (i) 437,919 NLS Common Shares, (ii) 2,971 NLS Common Shares issuable upon exercise of options vested and exercisable within 60 days of March 28, 2025, (iii) 13,054 NLS Common Shares issuable upon exercise of common warrants exercisable within 60 days of March 28, 2025, (iv) 100,807 NLS Common Shares issuable upon exercise of common warrants exercisable within 60 days of March 28, 2025, subject to a beneficial ownership limitation of 9.99%, and (v) 1,925 NLS Common Shares issuable upon exercise of pre -fundedwarrants exercisable within 60 days of March 28, 2025, subject to a beneficial ownership limitation of 4.99%. The beneficial ownership limitation restricts from exercising that portion of the warrants that would result in Mr. Ronald Hafner owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr. Hafner is Chairman of NLS Pharmaceutics Ltd. (4)Consists of (i) 1,578,997 NLS Common Shares, and (ii) 311,645